Pharmacokinetics of aprepitant after single and multiple oral doses in healthy volunteers

Journal of Clinical Pharmacology

Volumn 46, Issue 3, 2006, Pages 291-300

  Majumdar, Anup K ^a   Howard, Laura ^a   Goldberg, Michael R ^a   Hickey, Lisa ^a   Constanzer, Marvin ^a   Rothenberg, Paul L ^a   Crumley, Tami M ^a   Panebianco, Deborah ^a   Bradstreet, Thomas E ^a   Bergman, Arthur J ^a   Waldman, Scott A ^b   Greenberg, Howard E ^b   Butler, Kathleen ^b   Knops, A ^c   De Lepeleire, Inge ^a   Michiels, Nicole ^a   Petty, Kevin J ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

^c SGS Medisearch International NV   (Belgium)

Author keywords

Aprepitant; Bioavailability; Food effect; Pharmacokinetics

Indexed keywords

APREPITANT; PLACEBO; POLYSORBATE 80;

ADULT; AREA UNDER THE CURVE; ARTICLE; ASTHENIA; CHEMOTHERAPY INDUCED EMESIS; CONTROLLED STUDY; CYANOSIS; DIARRHEA; DIET RESTRICTION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CAPSULE; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; DYSPNEA; FATIGUE; FEMALE; FOOD INTAKE; HOT FLUSH; HUMAN; HUMAN EXPERIMENT; INJECTION SITE REACTION; MALE; MEDICAL ASSESSMENT; NAUSEA AND VOMITING; NORMAL HUMAN; SINGLE DRUG DOSE; TABLET FORMULATION; THORAX PAIN;

ADMINISTRATION, ORAL; ADULT; ANTIEMETICS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CAPSULES; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG MONITORING; FEMALE; FOOD-DRUG INTERACTIONS; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; MORPHOLINES; RECEPTORS, NEUROKININ-1;

EID: 32944458444     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/0091270005283467     Document Type: Article

References (14)

1. Arai H, Emson PC. Regional distribution of neuropeptide K and other tachykinins (neurokinin A, neurokinin B and substance P) in rat central nervous system. Brain Res. 1986 ; 399: 240-249.
2. Brodin E, Agran SO, Theodorsoon-Norheim E. Effects of subchronic treatment with imipramine, zimelidine and alaproclate on regional tissue levels of substance P and neurokinin A/neurokinin B-like immunoreactivity in the brain and spinal chord of the rat. Neuropharmacology. 1987 ; 26: 581-590.
3. Hokfelt T, Johansson O, Holets V, Meister B, Melander T. Distribution of neuropeptides with special reference to their coexistence with classical transmitter. In: Meltzer HY, ed. Psychopharmacology: The Third Generation of Progress. New York, NY: Raven Press ; 1987: 401-416.
4. Mantyh PW, Hunt SP, Maggio JE. Substance P receptors: localization by light microscopic autoradiography in rat brain using [3H]SP as the radioligand. Brain Res. 1984 ; 307: 147-165.
5. Campos D, Pereira JR, Reinhardt RR, et al. Prevention of cisplatininduced emesis by the oral neurokinin-1 antagonist, MK-869, in combination with granisetron and dexamethasone or with dexamethasone alone. J Clin Oncol. 2001 ; 19: 1759-1767.
6. Cocquyt V, Van Belle S, Reinhardt RR, et al. Comparison of L-758,298, a prodrug for the selective neurokinin-1 antagonist, L-754,030, with ondansetron for the prevention of cisplatin-induced emesis. Eur J Cancer. 2001 ; 37: 835-842.
7. Navari RM, Reinhardt RR, Gralla RJ, et al. Reduction of cisplatininduced emesis by a selective neurokinin-1-receptor antagonist. N Engl J Med. 1999 ; 340: 190-195.
8. Van Belle S, Lichinitser MR, Navari RM, et al. Prevention of cisplatin-induced acute and delayed emesis by the selective neurokinin-1 antagonists, L-758,298 andMK-869: a randomized controlled trial. Cancer. 2002 ; 94: 3032-3041.
9. Hesketh PJ, Grunberg SM, Gralla RJ, et al. The oral NK1 antagonist aprepitant for the prevention of chemotherapy induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin. J Clin Oncol. 2003 ; 21: 4112-4119.
10. Poli-Bigelli S, Rodriguez-Pereira J, Carides AD, et al. Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting: results from a randomized, double-blind, placebo controlled trial in Latin America. Cancer. 2003 ; 97: 3090-3098.
11. Constanzer ML, Chavez-Eng CM, Dru J, Kline WF, Matuszewski BK. Determination of a novel substance P inhibitor in human plasma by high-performance liquid chromatography with atmospheric pressure chemical ionization mass spectrometric detection using single and triple quadrupole detectors. J Chromatogr B. 2004 ; 807: 243-250.
12. Shelley WB, Talanin N, Shelley ED. Polysorbate 80 hypersensitivity. Lancet. 1995 ; 345: 1312-1313.
13. Sanchez RI, Wang R, Newton D, et al. Cytochrome P450 3A4 is the major enzyme involved in the metabolism of the substance P receptor antagonist aprepitant. Drug Metab Dispos. 2004 ; 32: 1287-1292.
14. Majumdar AK, McCrea JB, Panebianco DL, et al. Effect of aprepitant on cytochrome P450 3A4 activity using midazolam as a probe. Clin Pharmacol Ther. 2003 ; 74: 150-156.